top of page

CVS and Walgreens Expand Access to Mifepristone for Medication Abortions

In a landmark development for reproductive health care accessibility, CVS and Walgreens have announced plans to offer mifepristone, a medication commonly used in combination with others to terminate pregnancies in the early stages, at select locations across the United States. This move is set to significantly enhance access to reproductive health care options for individuals seeking abortion services.


CVS disclosed to CNN that it will commence filling prescriptions for mifepristone in Massachusetts and Rhode Island "in the weeks ahead," with intentions to expand to additional states where permitted by law on a rolling basis. Similarly, Walgreens also anticipates initiating mifepristone dispensing within a week, adhering to federal and state regulations, and will initially introduce this service in select locations in New York, Pennsylvania, Massachusetts, California, and Illinois. Both pharmacy giants underscored their commitment to ensuring quality, safety, and privacy throughout the rollout process.


The decision by CVS and Walgreens to offer mifepristone aligns with recent updates to FDA guidelines, issued in January 2023, which allow certified pharmacies to dispense the drug upon a prescription from a certified prescriber. Previously, the FDA mandated that certified prescribers distribute mifepristone directly to patients at clinics, medical offices, or hospitals, a requirement known as the "in-person dispensing requirement." However, this regulation was temporarily relaxed during the COVID-19 pandemic to facilitate access through mail-order pharmacies.


Mifepristone, approved by the FDA for use up to 10 weeks into pregnancy, has been the subject of legal challenges in the United States, with the Supreme Court slated to review its accessibility. Nonetheless, President Joe Biden hailed the news as a significant milestone in reproductive health care, emphasizing the drug's safety and effectiveness over the past two decades.


Advocates and experts have welcomed the expansion of mifepristone access as well, citing its potential to empower individuals seeking abortion services and improve overall reproductive health care outcomes. Dr. Daniel Grossman, a professor and vice chair of advocacy in the Department of Obstetrics, Gynecology, and Reproductive Sciences at the University of California, San Francisco, described the development as "good news," and highlighted the safety and efficacy of medication abortion when dispensed through certified pharmacies.


However, not all reactions to the news have been positive. Organizations opposed to abortion, such as the Human Coalition, have criticized the expansion of mifepristone access, labeling it as a "massive scheme of abortion-on-demand." Despite such opposition, advocates remain steadfast in their support for reproductive rights, viewing increased access to mifepristone as a crucial step towards ensuring comprehensive and equitable reproductive health care for all individuals.


As CVS and Walgreens prepare to introduce mifepristone dispensing services, the landscape of reproductive health care in the United States stands poised for transformation, with implications that extend far beyond pharmacy counters.

Comments


bottom of page